Basiron® AC (Basiron® AC)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceBenzoyl peroxideBenzoyl peroxide
Similar drugsTo uncover
  • Basiron® AC
    gel externally 
    Galderma S.A.     Switzerland
  • Eklaran 10
    gel externally 
    Pierre Fabre Dermatology     France
  • Eklaran 5
    gel externally 
    Pierre Fabre Dermatology     France
    • Dosage form: & nbsp

    gel for external use

    Composition:
    in 100 g of gel contains
    active substance: benzoyl peroxide aqueous (in terms of benzoyl peroxide anhydrous)
    Basiron AC 2,5% - 2,5 g,
    Baziron AC 5.0% 5.0 g,
    Baziron AC 10.0% - 10.0 g,
    Excipients:
    methacrylic acid copolymer 2.0 g, poloxamer 182 0.2 g, carbomer 940 0.8 g, glycerol 4.0 g, disodium edetate OD g, docusate sodium 0.05 g, propylene glycol 4.0 g, silicon colloidal dioxide -0,021 g, sodium hydroxide-up to pH 5.1-5.5, purified water - up to 100 g.
    Description:

    White homogeneous gel.

    Pharmacotherapeutic group:Antiseptic.
    ATX: & nbsp

    D.10.A.E.01   Benzoyl peroxide

    Pharmacodynamics:

    Benzoyl peroxide exhibits antimicrobial activity against Propionibacterium acnes and Staphylococcus epidermidis. It has a keratolytic effect, improves oxygenation of tissues, inhibits the production of sebum in the sebaceous glands.

    Pharmacokinetics:

    Penetration of benzoyl peroxide through the skin is low. The bulk of the benzoyl peroxide is converted to benzoic acid, which after absorption is introduced into the systemic circulation and rapidly excreted by the kidneys. There is no cumulation in the tissues.

    Dense application of Bazirone AS in therapeutic doses does not lead to side effects of systemic action.

    Indications:

    Acne.

    Contraindications:

    Hypersensitivity to one of the incoming ingredients of the drug. Children under 12 years.

    Pregnancy and lactation:

    Controlled clinical trials of the drug during pregnancy and lactation were not conducted. For a long time of clinical use of Baziron AS there were no cases of toxic effects on the fetus or malformations.

    The use of Baziron AS gel during pregnancy and breastfeeding is possible when the intended benefit to the mother exceeds the potential risk to the fetus.

    Dosing and Administration:

    Outwardly. With a gentle touch, apply the gel evenly to the affected area once or twice a day (morning and evening) on ​​clean, dry skin. The therapeutic effect develops after 4 weeks of treatment, a persistent improvement after 3 months of treatment.

    Repeated treatment is possible after consultation with a doctor.

    Side effects:

    In rare cases, local irritation (redness, peeling, dry skin, burning sensation).In such cases, it is recommended to reduce the frequency of application.

    In rare cases, allergic contact dermatitis may occur.

    Special instructions:

    Avoid getting Baziron AS gel on the mucous membranes of the eyes, mouth and nose. In case of accidental ingestion of the drug on mucous membranes, rinse thoroughly with warm water.

    It is not recommended simultaneous use of funds with exfoliating, drying or irritating effect (for example, products containing alcohol). Sun and ultraviolet irradiation are not recommended, which are an additional cause of skin irritation.

    Form release / dosage:

    Gel for external use 2.5%, 5%, 10%.

    Packaging:For 40 g of gel in a tube of low-density polyethylene with a tightly screwed lid. One tube with instructions for use is placed in a cardboard box.
    Storage conditions:
    At a temperature of no higher than 25 ° C. Do not freeze.
    Keep out of the reach of children.
    Shelf life:
    2 years: Do not use after expiry date.
    Terms of leave from pharmacies:Without recipe
    Registration number:П N014057 / 01
    Date of registration:17.04.2008
    The owner of the registration certificate: Galderma S.A. Galderma S.A. Switzerland
    Manufacturer: & nbsp
    GALDERMA, SA Switzerland
    Representation: & nbspGALDERMA, LLCGALDERMA, LLCRussia
    Information update date: & nbsp18.11.2014
    Illustrated instructions
      Instructions
      Up